Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating ... - BioSpace
Repare Therapeutics to present TRESR trial data on camonsertib monotherapy at ESMO Congress on Sept 14. The Phase 1/2 study aims to establish the recommended Phase 2 dose and evaluate safety, pharmacokinetics, and preliminary anti-tumor activity in patients with solid tumors.
Related Clinical Trials
Reference News
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating ... - BioSpace
Repare Therapeutics to present TRESR trial data on camonsertib monotherapy at ESMO Congress on Sept 14. The Phase 1/2 study aims to establish the recommended Phase 2 dose and evaluate safety, pharmacokinetics, and preliminary anti-tumor activity in patients with solid tumors.